A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design.
机构：[1]Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China[2]Department of Interventional Radiology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[3]Department of Interventional Radiology and Vascular Surgery, Hunan Provincial People’s Hospital, Changsha, China[4]Department of Radiology, Anhui Provincial Hospital, Hefei, China[5]Second Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[6]Department of Hepatobiliary Surgery & Vascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[7]Department of Interventional Medicine, The First Affiliated Hospital of Lanzhou University, Lanzhou, China[8]Department of Interventional Radiology, The First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, China[9]Department of Radiology, The Southwest Hospital, Third Military Medical University, Chongqing, China[10]Cancer Treatment Center, BaogangHospital of Inner Mongolia, Baotou, China[11]Department of Interventional Radiology,Hunan Cancer Hospital of Central South University, Changsha, China[12]Department of Interventional Therapy, Tumor Hospital of Guangxi Medical University, Nanning, China[13]Department of Medical Statistics, Fourth Military Medical University, Xi'an, China[14]Centre HospitalierUniversitaireVaudois and University of Lausanne, Department of Radiology, Lausanne, Switzerland
第一作者机构：[1]Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China[2]Department of Interventional Radiology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China[3]Department of Interventional Radiology and Vascular Surgery, Hunan Provincial People’s Hospital, Changsha, China[4]Department of Radiology, Anhui Provincial Hospital, Hefei, China[5]Second Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[6]Department of Hepatobiliary Surgery & Vascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[7]Department of Interventional Medicine, The First Affiliated Hospital of Lanzhou University, Lanzhou, China[8]Department of Interventional Radiology, The First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, China[9]Department of Radiology, The Southwest Hospital, Third Military Medical University, Chongqing, China[10]Cancer Treatment Center, BaogangHospital of Inner Mongolia, Baotou, China[11]Department of Interventional Radiology,Hunan Cancer Hospital of Central South University, Changsha, China[12]Department of Interventional Therapy, Tumor Hospital of Guangxi Medical University, Nanning, China[13]Department of Medical Statistics, Fourth Military Medical University, Xi'an, China[14]Centre HospitalierUniversitaireVaudois and University of Lausanne, Department of Radiology, Lausanne, Switzerland
推荐引用方式(GB/T 7714)：
Zhao Yan,Li Hailiang,Bai Wei,et al.A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design.[J].JOURNAL OF CLINICAL ONCOLOGY.2015,33(15):doi:10.1200/jco.2015.33.15_suppl.4080.
APA：
Zhao, Yan,Li, Hailiang,Bai, Wei,Liu, Jueshi,Lv, Weifu...&Han, Guohong.(2015).A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design..JOURNAL OF CLINICAL ONCOLOGY,33,(15)
MLA：
Zhao, Yan,et al."A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design.".JOURNAL OF CLINICAL ONCOLOGY 33..15(2015)
医学